A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry Disease (NCT03737214)

🧪 Interventions in This Study

• Lucerastat (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (42 Sites)

Showing the first 25 of 42 sites.

• University of Alabama at Birmingham - Nephrology Research Clinic — Birmingham, Alabama
• University of California Irvine — Irvine, California
• UCSF Benioff Children's Hospital Oakland — Oakland, California
• University of Florida Clinical and Translational Science Institute, UF Clinical Research Center — Gainesville, Florida
• Rush University Medical Center - Dept of Pediatrics — Chicago, Illinois
• University of Iowa Stead Family Children's Hospital - Division of Medical Genetics — Iowa City, Iowa
• Massachusetts General Hospital — Boston, Massachusetts
• Infusion Associates — Grand Rapids, Michigan
• University of Pennsylvania - Dept of Medicine — Philadelphia, Pennsylvania
• Greenwood Genetics Center — Greenville, South Carolina
• Renal Disease Research Institute LLC — Dallas, Texas
• Baylore University Medical Center — Dallas, Texas
• University of Utah - Division of Medical Genetics, Clinical Genetics Research — Salt Lake City, Utah
• Lysosomal and Rare Disorders Research and Treatment Center, Inc. — Fairfax, Virginia
• Royal Melbourne Hospital - Department of Nephrology — Parkville,
• Royal Perth Hospital, Department of Nephrology — Perth,
• Medizinische Universität Wien, Universitätsklinik für Innere Medizin III, Klinische Abteilung für Nephrologie und Dialyse — Vienna,
• University Hospital Ghent (UZ Ghent) — Ghent,
• University Hospital Gasthuisberg, Leuven (UZ Leuven) — Leuven,
• University of Calgary - Heritage Medical Research Clinic — Calgary,
• London Health Sciences CTR, Victoria Hospital — London,
• Research Center, Hôpital du Sacré-Coeur de Montréal — Montreal,
• Vancouver General Hospital - Adult Metabolic Diseases Clinic — Vancouver,
• Children's Hospital Research Institute of Manitoba — Winnipeg,
• Raymond Poincaré Hosp - Med Genetics Dept — Garches,

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Fabry Disease

• A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease — Birmingham, Alabama
• Long-Term Follow-up of Subjects Who Were Treated With ST-920 — Irvine, California
• An Open-label, Phase 1/2 Trial of Gene Therapy 4D-310 in Adults With Fabry Disease — La Jolla, California
• A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease — Birmingham, Alabama
• A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease — Atlanta, Georgia

Explore by condition: All Fabry Disease clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.